➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
Dow
Mallinckrodt
AstraZeneca
Moodys
Johnson and Johnson

Last Updated: February 25, 2021

DrugPatentWatch Database Preview

ISRADIPINE Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which patents cover Isradipine, and when can generic versions of Isradipine launch?

Isradipine is a drug marketed by Elite Labs Inc, Watson Labs Teva, and Mylan. and is included in three NDAs.

The generic ingredient in ISRADIPINE is isradipine. There are seven drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the isradipine profile page.

US ANDA Litigation and Generic Entry Outlook for Isradipine

A generic version of ISRADIPINE was approved as isradipine by WATSON LABS TEVA on January 5th, 2006.

  Start Trial

Drug patent expirations by year for ISRADIPINE
Drug Prices for ISRADIPINE

See drug prices for ISRADIPINE

Recent Clinical Trials for ISRADIPINE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University of Texas at AustinEarly Phase 1
National Institute of Neurological Disorders and Stroke (NINDS)Phase 3
The Parkinson Study GroupPhase 3

See all ISRADIPINE clinical trials

Pharmacology for ISRADIPINE
Medical Subject Heading (MeSH) Categories for ISRADIPINE

US Patents and Regulatory Information for ISRADIPINE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Elite Labs Inc ISRADIPINE isradipine CAPSULE;ORAL 077169-001 Apr 24, 2006 AB RX No No   Start Trial   Start Trial   Start Trial
Watson Labs Teva ISRADIPINE isradipine CAPSULE;ORAL 077317-002 Jan 5, 2006 AB RX No Yes   Start Trial   Start Trial   Start Trial
Elite Labs Inc ISRADIPINE isradipine CAPSULE;ORAL 077169-002 Apr 24, 2006 AB RX No No   Start Trial   Start Trial   Start Trial
Watson Labs Teva ISRADIPINE isradipine CAPSULE;ORAL 077317-001 Jan 5, 2006 AB RX No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Mallinckrodt
Harvard Business School
Dow
McKesson
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.